2′-,5′-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-α2b plus ribavirin therapy in patients with chronic hepatitis C

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 5, 2006, Pages 441-446

  Kim, K I ^a   Kim, S R ^a   Sasase, N ^a   Taniguchi, M ^a   Harada, S ^a   Kinoshita, K ^a   Kim, S H ^a   Akimoto, Y ^a   Shikata, M ^a   Kimura, N ^a   Izawa, S ^a   Ohtani, A ^a   Nakao, K ^a   Motojima, M ^b   Kinoshita, M ^b   Hirai, M ^b   Ohzu, M ^c   Hirooka, T ^c   Nabeshima, S ^c   Ishii, F ^c   Tanaka, K ^c   Hotta, H ^d   more..

^a KOBE ASAHI HOSPITAL   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2 ,5 oligoadenylate synthetase; Chronic hepatitis C; PEG interferon 2b; Ribavirin

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BIOLOGICAL MARKER; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; RETROSPECTIVE STUDY; VIRUS LOAD; BLOOD; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 33748350693     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00761.x     Document Type: Article

References (25)

1. Hu KQ, Vierling JM, Redeker AG (2001) Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis, 8, 1-18.
2. Shiratori Y, Kato N, Yokosuka O et al. (1997) Prediction of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology, 113, 558-566.
3. Nakamura H, Ito H, Ogawa H et al. (1999) Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load. Hepato- Gastroenterology, 46, 1131-1139.
4. Chayama K, Suzuki F, Tsubota A et al. (2001) Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype. Journal of Virological Methods, 95, 33-45.
5. Manns MP, McHutchison JG, Gordon SC et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358, 958-965.
6. Schmidt A, Zilberstein A, Shulman L, Federman P, Berissi H, Revel M (1978) Interferon action: isolation of nuclease F, a translation inhibitor activated by interferon-induced (2′-5′) oligo-isoadenylate. FEBS Letters, 95, 257-264.
7. Nilsen TW, McCandless S, Baglioni C (1982) 2′, 5′-oligo(A)- activated endonuclease in NIH 3T3 mouse cells chronically infected with Moloney murine leukemia virus. Virology, 122, 498-502.
8. Karino Y, Hige S, Matsushima M, Miyazaki T, Toyota J (1994) Significance of 2′,5′-oligoadenylate synthetase activity and HCV genotype in IFN therapy for type C chronic hepatitis. Hokkaido Igaku Zasshi. Hokkaido Journal of Medical Science, 69, 1354-1359.
9. Toda K, Kumagai N, Iwabuchi N et al. (1997) 2-5AS activity in serum and peripheral blood mononuclear cells for chronic active hepatitis C and the relationship to clinical outcome of interferon therapy. Japan Journal of Clinical Immunology, 20, 428-436.
10. Tong WB, Zhang CY, Feng BF, Tao QM (1998) Establishment of a nonradioactive assay for 2′-5′ oligoadenylate synthetase and its application in chronic hepatitis C patients receiving interferon-alpha. World Journal of Gastroenterology, 4, 70-73.
11. Okamoto H, Sugiyama Y, Okada S et al. (1992) Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. Journal of General Virology, 73, 673-679.
12. Poynard T, Marcellin P, Lee SS et al. (1998) Randomized trial of interferon α 2b plus ribavirin for 48 weeks or 24 weeks versus interferon α 2b plus placebo for 48 weeksfor treatment of chronic infection with hepatitis C virus. Lancet, 352, 1426-1432.
13. Glue P, Rouzeir-Panis R, Raffanel C et al. (2000) A dose-ranging study of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C. Hepatology, 32, 647-653.
14. Yasui K, Okanoue T, Murakami Y et al. (1998) Dynamics of hepatitis C viremia following interferon-alpha administration. Journal of Infectious Diseases, 177, 1475-1479.
15. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282, 103-107.
16. Ampurdanes S, Olmedo E, Maluenda MD et al. (1996) Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. Journal of Hepatology, 25, 827-832.
17. Orito E, Mizokami M, Suzuki K et al. (1995) Loss of serum HCV-RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. Journal of Medical Virology, 46, 109-115.
18. Lee WM, Reddy R, Tong MJ et al. (1998) Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology, 28, 1411-1415.
19. Izumi N, Asahina Y, Kurosaki M et al. (2004) A comparison of the exponential decay slope between PEG-IFN alfa-2a/ribavirin and IFN alfa-2a/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. Intervirology, 47, 102-107.
20. Anonymous (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology, 36, S3.
21. Anonymous (2002) Consensus conference. Treatment of Hepatitis C. Agence Nationale d'Accreditation et d'Evaluation en Sante (ANAES). Gastroenté rologie clinique et biologique, 26, B303.
22. Buti M, Mendez C, Schaper M et al. (2004) Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferonα-2b plus ribavirin. Journal of Hepatology, 40, 527-532.
23. Veillon P, Payan C, Pcchio G, Maniez-Montreiul M, Guntz P, Lunel F (2003) Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. Journal of Clinical Microbiology, 41, 3212-3220.
24. Zanetti AR, Romano L, Brunetto M, Colombo M, Bellati G, Tackney C (2003) Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. Journal of Medical Virology, 70, 27-30.
25. Marek B, Kajdaniuk D, Mazurek U et al. (2005) TGF-β1 mRNA expression in liver biopsy specimens and TGF-β1 serum levels in patients with chronic hepatitis C before and after antiviral therapy. Journal of Clinical Pharmacy and Therapeutics, 30, 271-277.